<DOC>
	<DOC>NCT02186574</DOC>
	<brief_summary>The purpose of the study is to determine how effective preemptive tenofovir therapy is in preventing the re-activation of Hepatitis B infection, in patients who are receiving rituximab-based chemotherapy for Non-Hodgkin's Lymphoma. The rate of re-activation will be compared between patients who receive preemptive tenofovir and patients who receive tenofovir as needed.</brief_summary>
	<brief_title>Tenofovir to Prevent HBV Reactivation</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1. â‰¥ 18 years of age 2. Diagnosis of nonHodgkin's lymphoma to be treated with rituximabbased chemotherapy 3. HBsAg negative, antiHBc positive 1. Current therapy with known activity against HBV 2. Screening ALT &gt; 10 x ULN 3. Screening ALT &gt;2 and &lt;10 xULN with HBV DNA &gt; 2000 IU/mL (indicates active HBV infection despite HBsAg negative and require antiviral therapy) 4. Life expectancy &lt; 3 months 5. HBsAg positive 6. HIV coinfection 7. Active HCV coinfection (HCV RNA positive) 8. Creatinine clearance &lt;50 mL/min 9. Intolerance to tenofovir 10. Women of childbearing potential unwilling to take contraception during the study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Non-Hodgkin</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Tenofovir</keyword>
	<keyword>Viread</keyword>
</DOC>